An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients With Relapsed/Refractory Solid Tumors or Hematological Malignancies Who Have Mild, Moderate, and Severe Renal Impairment
Phase of Trial: Phase I
Latest Information Update: 23 Oct 2017
At a glance
- Drugs Belinostat (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Pharmacokinetics
- Sponsors Spectrum Pharmaceuticals
- 16 Oct 2017 Planned End Date changed from 1 Apr 2017 to 1 Dec 2018.
- 16 Oct 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Jun 2018.
- 04 Apr 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Mar 2017 as reported by ClinicalTrials.gov record.